What is William Blair’s Estimate for BMY FY2027 Earnings?

Bristol-Myers Squibb (NYSE:BMY) – Equities research analysts at William Blair decreased their FY2027 earnings per share estimates for Bristol-Myers Squibb in a note issued to investors on Wednesday, February 19th. William Blair analyst M. Phipps now expects that the biopharmaceutical company will post earnings per share of $6.50 for the year, down from their previous estimate of $7.70. The consensus estimate for Bristol-Myers Squibb’s current full-year earnings is $6.74 per share. William Blair also issued estimates for Bristol-Myers Squibb’s FY2028 earnings at $5.91 EPS.

Several other analysts also recently weighed in on BMY. Morgan Stanley boosted their price target on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an “underweight” rating in a research note on Tuesday, November 12th. Cantor Fitzgerald boosted their target price on Bristol-Myers Squibb from $50.00 to $55.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. BMO Capital Markets raised their price target on Bristol-Myers Squibb from $57.00 to $61.00 and gave the stock a “market perform” rating in a research report on Tuesday, November 12th. Truist Financial boosted their price objective on Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a research report on Wednesday, January 8th. Finally, Daiwa Capital Markets upgraded shares of Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a report on Wednesday, November 13th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $57.86.

Bristol-Myers Squibb Trading Up 0.6 %

Shares of BMY opened at $58.25 on Monday. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $61.10. The firm has a market cap of $118.21 billion, a price-to-earnings ratio of -13.18, a PEG ratio of 2.07 and a beta of 0.45. The firm has a 50 day moving average price of $57.05 and a 200-day moving average price of $54.56. The company has a debt-to-equity ratio of 2.90, a quick ratio of 1.15 and a current ratio of 1.25.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share for the quarter, beating analysts’ consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%.

Bristol-Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Friday, January 3rd were given a dividend of $0.62 per share. The ex-dividend date was Friday, January 3rd. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a dividend yield of 4.26%. Bristol-Myers Squibb’s payout ratio is currently -56.11%.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,823 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was bought at an average cost of $54.84 per share, with a total value of $99,973.32. Following the transaction, the executive vice president now directly owns 63,932 shares in the company, valued at approximately $3,506,030.88. The trade was a 2.94 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.09% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Bristol-Myers Squibb

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Heck Capital Advisors LLC purchased a new position in Bristol-Myers Squibb during the fourth quarter valued at $188,000. Leigh Baldwin & CO. LLC purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter worth about $534,000. Polar Asset Management Partners Inc. bought a new position in Bristol-Myers Squibb in the 4th quarter worth about $16,651,000. Hall Capital Management Co. Inc. purchased a new stake in Bristol-Myers Squibb during the 4th quarter valued at about $329,000. Finally, Ameriflex Group Inc. bought a new stake in Bristol-Myers Squibb during the 4th quarter valued at about $322,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.